rVSV-ZEBOV vaccine
Generated by GPT-5-miniExpansion Funnel Raw 59 → Dedup 0 → NER 0 → Enqueued 0
| rVSV-ZEBOV vaccine | |
|---|---|
| Name | rVSV-ZEBOV |
| Type | live recombinant vaccine |
| Target | Ebola virus (Zaire ebolavirus) |
| Developer | NewLink Genetics; Public Health Agency of Canada; Merck |
| Tradename | Ervebo |
| Routes | intramuscular |
rVSV-ZEBOV vaccine is a live recombinant vaccine developed to prevent disease caused by Zaire ebolavirus, a member of the Filoviridae family, and was deployed during major outbreaks in West Africa and the Democratic Republic of the Congo. The vaccine was developed through collaborations involving the Public Health Agency of Canada, NewLink Genetics, and Merck & Co., and evaluated in trials coordinated with organizations such as the World Health Organization, Centers for Disease Control and Prevention, and Médecins Sans Frontières. Regulatory decisions by agencies including the European Medicines Agency and the United States Food and Drug Administration followed emergency use and compassionate use programs during epidemics.
Background and development
Development began when researchers at the National Microbiology Laboratory of the Public Health Agency of Canada engineered a recombinant vesicular stomatitis virus vector expressing the glycoprotein of Zaire ebolavirus, inspired by earlier vector work at institutions like the University of Texas Medical Branch and the National Institutes of Health. Partnerships with biotechnology firms such as NewLink Genetics and later pharmaceutical companies including Merck & Co. accelerated preclinical studies that involved collaborators from the Walter Reed Army Institute of Research, the Institut Pasteur, and academic centers such as Harvard University and Johns Hopkins University. Field deployment planning engaged international actors including the World Health Organization, GAVI, the Vaccine Alliance, and the Global Health Security Agenda during the 2014–2016 Ebola epidemic in West Africa and the 2018–2020 Kivu Ebola epidemic.
Composition and mechanism of action
rVSV-ZEBOV uses a live attenuated recombinant vesicular stomatitis virus (VSV) backbone from studies at the Centers for Disease Control and Prevention and the Rockefeller University, into which the coding sequence for the Zaire ebolavirus surface glycoprotein was inserted, a strategy related to recombinant vector approaches previously used at the Salk Institute and Emory University. The vaccine induces humoral and cellular immunity by presenting the Ebola glycoprotein antigen to immune effectors, engaging pathways characterized in research from the National Institute of Allergy and Infectious Diseases and modeled in studies published by investigators at the University of Oxford and the London School of Hygiene & Tropical Medicine. Animal efficacy was demonstrated in nonhuman primate studies conducted at the United States Army Medical Research Institute of Infectious Diseases and the National Institutes of Health.
Clinical trials and efficacy
Efficacy evidence arose from randomized and ring-vaccination trials organized by the World Health Organization, Centre for the AIDS Programme of Research in South Africa, and research teams including those at the London School of Hygiene & Tropical Medicine, Noguchi Memorial Institute for Medical Research, and University of Kinshasa. The landmark ring vaccination trial in Guinea coordinated with partners such as Centers for Disease Control and Prevention, Médecins Sans Frontières, and the Norwegian Institute of Public Health reported high efficacy estimates, influencing subsequent policy by the World Health Organization and emergency use recommendations by the European Medicines Agency. Observational data from outbreak responses in Sierra Leone, Liberia, and the Democratic Republic of the Congo provided additional effectiveness data analyzed by teams at Harvard T.H. Chan School of Public Health and the Johns Hopkins Bloomberg School of Public Health.
Safety and adverse effects
Safety assessments were conducted in phase I–III trials overseen by institutional review boards at centers including NIH Clinical Center, McGill University Health Centre, and Kenema Government Hospital, and monitored by data safety monitoring boards affiliated with the World Health Organization and national regulatory bodies such as Health Canada. Common adverse events reported in trial publications from groups at University College London and Pasteur Institute included transient injection-site reactions, fever, myalgia, and headache; rare serious events included febrile reactions and neurologic symptoms investigated with input from specialists at the European Centre for Disease Prevention and Control and the US Department of Health and Human Services. Post-deployment surveillance by the Vaccine Adverse Event Reporting System and pharmacovigilance programs coordinated with GAVI, the Vaccine Alliance informed risk–benefit assessments.
Regulatory approval and deployment
Emergency use and compassionate use authorizations during outbreaks preceded formal approvals: emergency deployment was coordinated by the World Health Organization under investigational protocols, and later full marketing authorization was granted by the European Medicines Agency and the United States Food and Drug Administration as well as national regulatory authorities in affected countries, with manufacturing and distribution agreements involving Merck & Co. and procurement arranged through GAVI, the Vaccine Alliance and the United Nations procurement mechanisms. Deployment strategies used ring vaccination models developed from outbreak response experiences in Guinea and DR Congo, involving logistics partners such as UNICEF, World Food Programme, and humanitarian organizations like Médecins Sans Frontières.
Manufacturing and storage
Manufacturing scaled up through facilities operated by Merck & Co. with quality oversight referencing standards from the World Health Organization and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Cold-chain requirements necessitate storage and transport conditions similar to other live vaccines with ultra-cold considerations informed by guidance from agencies such as the Centers for Disease Control and Prevention and Pan American Health Organization; distribution in field settings leveraged logistics expertise from UNICEF and the World Food Programme during emergency responses in West Africa and Central Africa.
Impact and public health use
rVSV-ZEBOV had measurable impact on outbreak control in deployments analyzed by researchers at Johns Hopkins University, Imperial College London, and the World Health Organization, contributing to interruption of transmission chains when combined with contact tracing and case management protocols used by organizations such as Médecins Sans Frontières and national ministries of health in Guinea, Sierra Leone, and the Democratic Republic of the Congo. The vaccine’s development and deployment spurred policy discussions at forums including the World Health Assembly and initiatives led by GAVI, the Vaccine Alliance and the Global Fund about financing, equity, and preparedness for future hemorrhagic fever outbreaks. Continued surveillance, research at institutions like University of Oxford and National Institutes of Health, and inclusion in emergency response toolkits by the World Health Organization shape ongoing public health strategies.